News From Law.com
A proposed class action claim against drug makers Novo Nordisk, Eli Lilly, and Sanofi-Aventis alleging an unfair and unconscionable pricing scheme for analog insulin products has been denied class certification and a judge partially granted the defense's motion to exclude expert testimony.
Biotech & Pharmaceuticals
February 09, 2024, 1:37 PM